Merck KGaA Announces Chinese Approval for Abbisko's TGCT Treatment

03:35 AM EST, 12/22/2025 (MT Newswires) -- Merck KGaA (MRK.F) received China's National Medical Products Administration's approval for its pimicotinib treatment for tenosynovial giant cell tumor, or TGCT. The treatment is meant for adult patients with symptomatic TGCT in cases where surgical resection may cause functional limitation or relatively severe morbidity, according to a Monday release. The pharmaceutical giant noted that the approval follows a priority review. Pimicotinib was developed by Abbisko Therapeutics Co., and Merck holds the global commercialization rights.